Over 30 medical societies including the American College of Radiology recently wrote to CMS Administrator Mehmet C. Oz, MD, MBA, to voice their concerns. 

Breast imaging exams are about five times likelier to be canceled than other scan types, while contrast enhanced and ED-related requests were about twice as likely. 

Many if not most healthcare AI vendors market tweaked versions of large language models developed by other, usually larger companies. The lack of originality isn’t just a superficial concern. It may burden adopting healthcare organizations with practical, clinical and even legal risks. For clients of the radiology technology company CIVIE, formerly known as Collaborative Imaging, those worries are soon to be things of the past. 

CEO Dana Smetherman, MD, MPH, MBA, explains how the consolidation of radiology practices has shifted how the college thinks about its processes. 

New Zealand-based Wellumio in January announced its expansion into the U.S., laying the groundwork for local clinical trials to test its device.  

Though this finding is relatively uncommon, it is expected that the BI-RADS 6th edition ultrasound lexicon will include it as a feature associated with malignancy.

Large language models have shown great potential in medical imaging, but their success has been hindered by their wavering effectiveness. Now, nearly three years after ChatGPT's release, experts are sharing new insights. 

Getting healthcare AI to fulfill its destiny—can we call it that now?—will require ‘scenario-based’ consideration of every use case.

The federal payment program first started paying for AI in 2018 and has denied about 53% of claims (or 53,857) submitted by radiologists since then, experts detail in JACR. 

Plaintiff attorneys claim the Massachusetts-based company shattered the competitive position of Pylarify, a PET imaging agent for prostate cancer.